Amendment #1 Cooperative Research and Development Agreement # 02716 “Cooperative Research and Development Agreement for the Development of NCI Proprietary Peripheral Blood Autologous T Cell Therapies Using Genetically Modified Peripheral Blood...Kite Pharma, Inc. • May 15th, 2015 • Biological products, (no disgnostic substances)
The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA remain in full force and effect. Two originals of this amendment are provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.
FIRST AMENDMENT TO STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NETKite Pharma, Inc. • May 15th, 2015 • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO STANDARD INDUSTRIAL /COMMERCIAL SINGLE-TENANT LEASE - NET is dated as of April 27, 2015 (this "First Amendment"), is entered into by and between 2355 UTAH INDUSTRIAL CAPITAL, LLC, a California limited liability company ("Lessor"), and KITE PHARMA, INC., a Delaware corporation ("Lessee"), with reference to the following:
